The 2012 Cochrane Review on “Pharmacotherapy for Mild Hypertension”1 concluded that antihypertensive drugs used in the treatment of otherwise healthy adults with mild hypertension (systolic blood pressure [BP], 140-159 mm Hg, and/or diastolic BP, 90-99 mm Hg) have not been shown to reduce mortality or morbidity in randomized clinical trials. Will this landmark conclusion affect clinical practice and slow the inexorable expansion of disease categories? It certainly should because overdiagnosis and overtreatment are potent causes of both waste and harm and seem to be operating in the interests of the pharmaceutical industry rather than in those of the patients whom the industry claims to serve.
Heath I. Waste and Harm in the Treatment of Mild Hypertension. JAMA Intern Med. 2013;173(11):956–957. doi:10.1001/jamainternmed.2013.970
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: